Salesforce targets pharmaceutical sector with new life sciences software

Salesforce Inc., a prominent player in the customer relationship management (CRM) software industry, is positioning itself for significant growth within the pharmaceutical sector, having recently attracted more than 40 clients, including leading global pharmaceutical companies, to its forthcoming life sciences software. This development marks a pivotal shift as the company seeks to establish a stronghold in a market traditionally dominated by its former partner, Veeva Systems Inc.

According to Jeff Amann, executive vice president of industry-specific software lines at Salesforce, several of these new clients are shifting their allegiance from Veeva Systems, signalling increased competition in the pharmaceutical CRM space. “When Veeva made the decision to go its own way, many of those customers came to us and said ‘We don’t want to leave,’” Amann stated in a commentary outlining Salesforce’s strategy.

Veeva Systems has long been recognised as a formidable entity in pharmaceutical CRM, boasting a market share exceeding 80% and generating a projected annual revenue of approximately $2.72 billion for the year ending January. Dylan Baker, an analyst at William Blair, referenced Veeva’s established position in a recent analysis, highlighting the company’s suite of products that aid in drug development tracking and analytics.

Once reliant on Salesforce’s platform, Veeva had previously operated under a non-aggression agreement with Salesforce since 2007, which allowed it to flourish without direct competition. However, the partnership was effectively dissolved in late 2022 when Veeva announced plans to expand its own offerings. Following this announcement, Salesforce seized the opportunity to design its competing product and commence efforts to attract Veeva’s former clients.

The competitive landscape has also influenced Veeva’s stock performance, as shares reportedly fell by up to 4.7% mid-week, while Salesforce’s stock remained relatively stable. This situation reflects the dynamics at play in the software market for life sciences, where Salesforce identifies a unique opportunity for penetration, having previously been limited in this sector.

In an effort to meet demand amidst the competitive push, Salesforce is actively hiring development teams to support the impending launch of its life sciences product. The product is scheduled for debut in September, and Amann has confirmed that the company is currently engaged in “active discussions” with several large pharmaceutical organisations regarding its adoption.

Salesforce’s recent advances in utilising artificial intelligence (AI) within its offerings, alongside enhanced data integration tools, are part of its strategy to reignite revenue growth following a slowdown in recent years. The pharmaceutical sector thus represents a crucial opportunity for Salesforce to diversify its services and enhance its market position, offering innovative solutions tailored for life sciences at a time when emerging technologies are revolutionising business practices across industries.

Source: Noah Wire Services